Holen Sie sich die Stockscreener-App
30.61
4.73%
-1.52
Handel nachbörslich:
31.05
0.44
+1.44%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CYTK?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$32.13
Offen:
$32.35
24-Stunden-Volumen:
3.47M
Relative Volume:
1.63
Marktkapitalisierung:
$4.06B
Einnahmen:
$18.47M
Nettoeinkommen (Verlust:
$-589.53M
KGV:
-5.8194
EPS:
-5.26
Netto-Cashflow:
$-399.80M
1W Leistung:
-9.89%
1M Leistung:
-20.80%
6M Leistung:
-45.30%
1J Leistung:
-47.12%
1-Tages-Spanne:
$30.46
$32.95
1-Wochen-Bereich:
$30.46
$35.36
52-Wochen-Spanne:
$30.46
$61.40
Cytokinetics Inc Stock (CYTK) Company Profile
Firmenname
Cytokinetics Inc
Sektor
Branche
Telefon
(650) 624-3000
Adresse
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Vergleichen Sie CYTK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
30.61 | 4.06B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-24 | Eingeleitet | Barclays | Overweight |
| 2025-02-07 | Eingeleitet | Citigroup | Buy |
| 2025-01-22 | Eingeleitet | Stifel | Buy |
| 2024-11-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-13 | Herabstufung | Goldman | Buy → Neutral |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2024-01-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-07 | Eingeleitet | B. Riley Securities | Buy |
| 2023-08-15 | Eingeleitet | SVB Securities | Outperform |
| 2023-02-17 | Eingeleitet | BofA Securities | Neutral |
| 2022-12-23 | Bestätigt | Needham | Buy |
| 2022-12-20 | Eingeleitet | Truist | Buy |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-01-28 | Eingeleitet | Goldman | Buy |
| 2021-12-22 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-10 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2021-02-18 | Eingeleitet | Barclays | Overweight |
| 2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-29 | Eingeleitet | Goldman | Neutral |
| 2020-07-10 | Eingeleitet | Raymond James | Strong Buy |
| 2020-05-05 | Eingeleitet | Mizuho | Buy |
| 2020-04-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Bestätigt | Morgan Stanley | Overweight |
| 2017-11-22 | Herabstufung | Needham | Strong Buy → Buy |
| 2017-11-21 | Bestätigt | H.C. Wainwright | Buy |
| 2017-07-31 | Eingeleitet | Morgan Stanley | Overweight |
| 2017-03-08 | Eingeleitet | Rodman & Renshaw | Buy |
| 2017-02-06 | Hochstufung | Needham | Buy → Strong Buy |
| 2016-12-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Bestätigt | Needham | Buy |
| 2015-11-10 | Bestätigt | FBR Capital | Outperform |
| 2015-11-09 | Bestätigt | ROTH Capital | Buy |
| 2015-07-24 | Bestätigt | MLV & Co | Buy |
| 2014-12-31 | Bestätigt | ROTH Capital | Buy |
| 2014-11-04 | Hochstufung | MLV & Co | Hold → Buy |
| 2014-04-28 | Bestätigt | Needham | Buy |
Alle ansehen
Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten
Cytokinetics Unusual Options Activity - Nasdaq
Cytokinetics gets an ‘incremental’ win for delayed heart drug - Endpoints News
Cytokinetics (CYTK) Rallies as Phase 3 Trial Succeeds for Lead D - GuruFocus
Cytokinetics stock rises on Phase 3 trial win (CYTK:NASDAQ) - Seeking Alpha
Cytokinetics (CYTK) Reports Positive Results from Phase 3 Clinical Trial | CYTK Stock News - GuruFocus
Cytokinetics Announces Positive Topline Results From MAPLE-HCM | CYTK Stock News - GuruFocus
Aficamten outperforms beta blocker in HCM trial - Investing.com
Cytokinetics' heart disease drug meets main goal in late-stage study - marketscreener.com
Cytokinetics Announces Positive Topline Results From MAPLE-HCM - Eagle-Tribune
Dimensional Fund Advisors LP Trims Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World
Cytokinetics, Incorporated Being Investigated on Behalf of Cytokinetics, Incorporated Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire
5,400 Shares in Cytokinetics, Incorporated (NASDAQ:CYTK) Bought by Raymond James Financial Inc. - Defense World
Cytokinetics, Incorporated Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for Details- CYTK - ACCESS Newswire
FY2025 EPS Estimates for Cytokinetics Lowered by Analyst - Defense World
Barclays Lowers Cytokinetics (NASDAQ:CYTK) Price Target to $53.00 - Defense World
HC Wainwright Has Weak Estimate for Cytokinetics Q2 Earnings - Defense World
What is B. Riley’s Estimate for Cytokinetics Q2 Earnings? - Defense World
Leerink Partnrs Predicts Lower Earnings for Cytokinetics - Defense World
Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma - insights.citeline.com
Royal Bank of Canada Issues Pessimistic Forecast for Cytokinetics (NASDAQ:CYTK) Stock Price - Defense World
Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress - Stock Titan
Cytokinetics, Incorporated (CYTK) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - Business Wire
Cytokinetics (CYTK) Maintains Overweight Rating Despite Price Target Cut | CYTK Stock News - GuruFocus
Levi & Korsinsky Announces an Investigation on Behalf of Cytokinetics, Incorporated (CYTK) Shareholders Who May Have Been Affected by Fraud - ACCESS Newswire
B. Riley Adjusts Cytokinetics Price Target to $74 From $88, Maintains Buy Rating - marketscreener.com
Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2025 Earnings Call Transcript - Insider Monkey
Cytokinetics First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Cytokinetics shares hold as JMP reiterates $78 price target By Investing.com - Investing.com Nigeria
Cytokinetics (NASDAQ:CYTK) Sets New 12-Month Low Following Analyst Downgrade - Defense World
Cytokinetics at The Citizens JMP Life Sciences Conference: Strategic Insights By Investing.com - Investing.com Nigeria
Shareholders that lost money on Cytokinetics, Incorporated (CYTK) should contact Levi & Korsinsky about Securities Fraud InvestigationCYTK - ACCESS Newswire
CYTK: Citigroup Lowers Price Target for Cytokinetics | CYTK Stoc - GuruFocus
Cytokinetics Inc earnings beat by $0.01, revenue fell short of estimates - Investing.com Nigeria
Cytokinetics to Hold Annual Meeting of Stockholders - Stock Titan
Cytokinetics (CYTK) Price Target Adjusted by RBC Capital | CYTK Stock News - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Cytokinetics Q1 Earnings Beat, Aficamten Target Action Date Extended - Yahoo Finance
Cytokinetics: Strong Buy As FDA's 3-Month Delay Doesn't Derail Aficamten's Approval Outlook - Seeking Alpha
Cytokinetics at The Citizens JMP Life Sciences Conference: Strategic Insights - Investing.com Australia
Cytokinetics (CYTK) Price Target Adjusted as FDA Decision Delayed | CYTK Stock News - GuruFocus
Cytokinetics shares hold as JMP reiterates $78 price target - Investing.com
Insider Sell Alert: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics Inc (CYTK) Q1 2025 Earnings Call Highlights: Strong Start Amid Regulatory Challenges By GuruFocus - Investing.com Canada
Cytokinetics (CYTK) Advances Aficamten Commercialization Plans - GuruFocus
Cytokinetics Inc (CYTK) Q1 2025 Earnings Call Highlights: Strong Start Amid Regulatory Challenges - Yahoo Finance
Cytokinetics, Incorporated (NASDAQ:CYTK) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Cytokinetics: Q1 Earnings Snapshot - The Washington Post
Cytokinetics (CYTK) Misses Q1 Revenue Estimates and Advances Car - GuruFocus
Cytokinetics Inc (CYTK) Q1 2025 Earnings: EPS of -$1.36 Beats Es - GuruFocus
Earnings call transcript: Cytokinetics reports Q1 2025 net loss, stock dips - Investing.com India
Cytokinetics Q1 Net Loss Widens, Revenue Rises - marketscreener.com
Finanzdaten der Cytokinetics Inc-Aktie (CYTK)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):